260553-97-7
![260553-97-7 结构式](/CAS/20200611/GIF/260553-97-7.gif)
基本信息
3H-Imidazo[4,5-b]pyridine, 2-butyl-5-methyl-6-(3-pyridinyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
物理化学性质
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/08/19 | HY-112920 | TM-25659 TM-25659 | 260553-97-7 | 5mg | 950元 |
2024/08/19 | HY-112920 | TM-25659 TM-25659 | 260553-97-7 | 10mM * 1mLin DMSO | 1050元 |
2024/08/19 | HY-112920 | TM-25659 TM-25659 | 260553-97-7 | 10mg | 1500元 |
常见问题列表
TAZ
TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ.
TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation.
Cell Proliferation Assay
Cell Line: | 3T3-L1 cells |
Concentration: | 2, 10, 20, 100 μM |
Incubation Time: | 6 days |
Result: | Acted as a suppressor of PPARγ-dependent adipocyte differentiation [1] . |
TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model.
TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t 1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h -1 ×kg -1 and the volume of distribution at steady-state (1.91 L×h -1 ×kg -1 ) is larger than the volume of total body fluids.
Animal Model: | C57BL6 mice (4- to 6-week-old ) |
Dosage: | 50 mg/kg |
Administration: | I.p., every other day for 2 weeks |
Result: | Attenuated weight gain in these obese mice [1] . |
Animal Model: | Adult male Sprague-Dawley rats |
Dosage: | 10 mg/kg |
Administration: | I.v. (2, 10 and 30 min), oral (15 and 30 min, and 1, 2, 4 and 8 h) |
Result: | Oral administration for 4 weeks moderately but significantly attenuated weight gain and partly restored BMD in the OVX rats [1] . |